400-859-2883
Your location:Home >News center >Industry News

Industry News

04-262021

Application of Lipid Nanoparticles in COV…

The use of lipid nanoparticles (LNPs) in BioNTech/Pfizer and Moderna COVID-19 mRNA vaccines.

Application of Lipid Nanoparticles in COVID-19 mRNA Vaccines
04-152021

Brilacidin, A Candidate Drug For The Trea…

The Brilacidin trial for the treatment of COVID-19 infection has started in February 2021 and is expected to be completed in July 2021.

Brilacidin, A Candidate Drug For The Treatment of COVID-19
03-242021

The Development History of Tamiflu Oselta…

The Development History of Tamiflu Oseltamivir

The Development History of Tamiflu Oseltamivir
01-042021

What is the Difference Between API and Ph…

API is a compound that can be safely used in the human body for therapeutic diagnosis after sufficient pharmaceutical research. The pharmaceutical intermediate is a compound in the process of…

What is the Difference Between API and Pharmaceutical Intermediates?
07-142020

Antidiabetic Drugs Classification and Mec…

This article gives you information about antidiabetic drugs classification and their mechanism of action.

Antidiabetic Drugs Classification and Mechanism of Action
12-042019

Baloxavir Marboxil for Uncomplicated Infl…

Baloxavir marboxil, marketed as Xofluza, is a first-in-class, one-dose oral agent first approved by the FDA in 2018 for the treatment of acute, uncomplicated influenza in individuals 12 years…

Baloxavir Marboxil for Uncomplicated Influenza: Mechanism of Action & Side Effects